

PIPEX PHARMACEUTICALS, INC.

Form 4

April 15, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
KANZER STEVE H

(Last) (First) (Middle)

C/O 3930 VARSITY DRIVE

(Street)

ANN ARBOR, MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PIPEX PHARMACEUTICALS, INC. [PP]

3. Date of Earliest Transaction (Month/Day/Year)
04/11/2008

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount		
Common Stock	04/11/2008		P		500	A	\$ 0.79 325,746 D
Common Stock	04/11/2008		P		9,500	A	\$ 0.8 335,246 D
Common Stock	04/11/2008		P		500	A	\$ 0.81 335,746 D
Common Stock	04/11/2008		P		2,300	A	\$ 0.83 338,046 D
Common Stock	04/11/2008		P		1,000	A	\$ 0.85 339,046 D

Edgar Filing: PIPEX PHARMACEUTICALS, INC. - Form 4

Common Stock	04/11/2008	P	6,200	A	\$ 0.86	345,246	D	
Common Stock	04/11/2008	P	2,400	A	\$ 0.89	347,646	D	
Common Stock	04/11/2008	P	500	A	\$ 0.9	348,146	D	
Common Stock	04/11/2008	P	100	A	\$ 0.91	348,246	D	
Common Stock	04/11/2008	P	9,900	A	\$ 0.92	358,146	D	
Common Stock	04/11/2008	P	8,484	A	\$ 0.93	366,630	D	
Common Stock	04/11/2008	P	2,650	A	\$ 0.94	369,280	D	
Common Stock	04/11/2008	P	1,866	A	\$ 0.95	371,146	D	
Common Stock	04/11/2008	P	1,000	A	\$ 0.96	372,146	D	
Common Stock	04/11/2008	P	3,100	A	\$ 0.98	375,246	D	
Common Stock	10/31/2006	P	7,086,380	A	Ⓐ	7,086,380	I	Accredited Venture Capital, LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or

Number
of
Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KANZER STEVE H C/O 3930 VARSITY DRIVE ANN ARBOR, MI 48108	X		Chief Executive Officer	

Signatures

/s/ Steve H.
Kanzer

04/14/2008

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Received in exchange for shares of Pipex Therapeutics, Inc. common stock upon the October 31, 2006 merger of Pipex Therapeutics, Inc. (1) and a wholly owned subsidiary of the Registrant. Mr. Kanzer is the managing member of Pharmainvestors, LLC, the managing member of Accredited Venture Capital, LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.